BEIJING, April 30, 2014 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and sleep respiratory products in China, today announced it has become the authorized agent of Olympus (Beijing) Sales & Service Co., Ltd. ("Olympus") to supply its electronic gastroscope and electronic bronchoscope products to participate in several medical device procurement projects funded by the Chinese government. Pursuant to the authorization letter with Olympus, Dehaier will be responsible for bidding, agreement negotiation and execution of the projects.
Mr. Ping Chen, the Chairman and CEO of Dehaier, commented, "Dehaier is pleased to serve as agent on behalf of Olympus to participate in several medical equipment procurement bids. Olympus gastroscope and bronchoscope products are popular in the industry and command a high market share. We are honored to be recognized by Olympus, one of the world's top companies in the healthcare sector. And we believe this relationship may benefit Dehaier in the short and long term."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including medical devices and sleep respiratory products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco (UK). Dehaier's technology is based on six patents and ten software copyrights. More information may be found at http://www.dehaier.com.cn
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.